Biological agents targeting interleukin-18

Drug News Perspect. 2007 Oct;20(8):485-94. doi: 10.1358/dnp.2007.20.8.1157617.

Abstract

Interleukin (IL)-18 is an important regulator of both innate and acquired immune responses. It is upregulated in several human autoimmune and inflammatory diseases, and, therefore, might represent a novel therapeutic target. This review highlights the biology of IL-18, its central role in inflammation and immune response, as well as provides evidence for the involvement of IL-18 in selected chronic inflammatory diseases. After that, the authors discuss various therapeutic strategies of IL-18 blockade in clinical and preclinical models, particularly the inhibition of IL-18 secretion, IL-18 binding protein, anti-IL-18 monoclonal antibodies and soluble IL-18 receptor.

Publication types

  • Review

MeSH terms

  • Animals
  • Biological Products / pharmacology*
  • Biological Products / therapeutic use
  • Humans
  • Immune System Diseases / drug therapy
  • Immune System Diseases / immunology
  • Immune System Diseases / metabolism
  • Interleukin-18 / antagonists & inhibitors*
  • Interleukin-18 / immunology
  • Interleukin-18 / metabolism
  • Models, Immunological
  • T-Lymphocyte Subsets / cytology
  • T-Lymphocyte Subsets / drug effects
  • T-Lymphocyte Subsets / immunology

Substances

  • Biological Products
  • Interleukin-18